Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betulonic acid is a naturally occurring lupane-type pentacyclic triterpenoid, primarily derived from the bark of birch trees (*Betula* species). Structurally, it is the 3-oxo analog of betulinic acid, featuring a ketone group at the C-3 position instead of a hydroxyl group. It is widely utilized in preclinical research due to its diverse biological activities, which include anti-tumor, anti-viral, anti-inflammatory, anti-bacterial, and hepatoprotective properties. Despite its pharmacological potential and its role as a chemical intermediate for the synthesis of more potent semisynthetic derivatives with improved bioavailability, betulonic acid has not been advanced into clinical trials by any pharmaceutical developer and remains a research compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betulonic acid.